Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Business Wire
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report. The inaugural report provides an overview of Legend Biotech’s ESG program and reporting in alignment with the Sustainable Accounting Standards Board (“SASB”) Biotechnology and Pharmaceutical sector standards, the Company’s ESG data collection and disclosure roadmap, and future growth areas in its ESG journey.“At Legend Biotech, we are united by our mission to deliver life-saving treatments to patients with intractable and incurable diseases. As one of the largest global cell therapy research and development teams in the industry, sustainable business practices are integral to helping us achieve this goal,” said Ying Huang, Chief Executive Officer of Legend Biotech. “We are proud to share our inaugural ESG report, highlighting our commitment to patients, employees, and our communit
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.MarketBeat
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma [Yahoo! Finance]Yahoo! Finance
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaBusiness Wire
- Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"PR Newswire
- Legend Biotech Co. (NASDAQ: LEGN) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $65.00 price target on the stock.MarketBeat
LEGN
Sec Filings
- 4/22/24 - Form 6-K
- 4/16/24 - Form 6-K
- 4/8/24 - Form 6-K
- LEGN's page on the SEC website